1. FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab for metastatic colorectal cancer (FIRE-3): a post-hoc analysis of tumour dynamics in the final RAS wild-type subgroup of this randomised open-label phase 3 trial. Issue 10 (October 2016) Authors: Stintzing, Sebastian; Modest, Dominik P; Rossius, Lisa; Lerch, Markus M; von Weikersthal, Ludwig Fischer; Decker, Thomas; Kiani, Alexander; Vehling-Kaiser, Ursula; Al-Batran, Salah-Eddin; Heintges, Tobias; Lerchenmüller, Christian; Kahl, Christoph; Seipelt, Gernot; Kullmann, Frank; Stauch, Martin... Journal: Lancet oncology Issue: Volume 17:Issue 10(2016:Oct.) Page Start: 1426 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗